Taiwan biotech Great Novel Therapeutics launches Phase I trial for GNTbm-38 cancer therapy
Great Novel Therapeutics launches Phase I trial of GNTbm-38 after FDA IND approval. Discover what this epigenetic cancer immunotherapy could change.
How Persevere Therapeutics plans to reposition misetionamide in a crowded ovarian cancer pipeline
Persevere Therapeutics launches misetionamide trial in platinum-resistant ovarian cancer. Discover what this dual-pathway strategy could mean for treatment.
Can Vyriad’s VV169 redefine CAR T therapy with single-dose in vivo delivery?
Vyriad secures $85M to launch VV169, its in vivo CAR T therapy for multiple myeloma. Find out how this platform could reshape cancer immunotherapy.